Therapeutic effect of clozapine in psychotic decompensation in idiopathic Parkinson's disease.
Seven patients with idiopathic Parkinson's disease, aged 62 to 76 years, average duration of the disease approximately eleven years, suffering from severe hallucinosis and paranoid delusions of different degree, in whom conventional therapeutic strategies (administration of benzodiazepines and mild neuroleptics) had no antipsychotic effect, received clozapine, a non-classical highly potent neuroleptic, while blood count was strictly monitored. Paranoid ideas disappeared in all seven patients after a maximum of four days administration of 25-125 mg/day. No deterioration of parkinsonian symptoms, quantified according to UPDRS was seen. Given the protection of clozapine, we could increase the L-dopa dose in two cases, thereby improving the patients' motor function. Blood count showed no abnormalities in any of the patients during an average observation period of seventeen months. Our results support the assumption that clozapine has a potent antipsychotic effect in the treatment of psychotic decompensation in advanced Parkinson's disease in carefully selected patients. We saw no negative influence of the neuroleptic on extrapyramidal symptoms.
Pinter
M M
MM
Neurological Hospital Rosenhügel, Vienna, Austria.
Helscher
R J
RJ
D000368:Aged; D001545:Benserazide / Q000627:therapeutic use; D001772:Blood Cell Count; D003024:Clozapine / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006212:Hallucinations / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010259:Paranoid Disorders / Q000188:drug therapy / Q000209:etiology; D010300:Parkinson Disease / Q000150:complications* / Q000188:drug therapy / Q000523:psychology; D011618:Psychotic Disorders / Q000188:drug therapy* / Q000209:etiology
D007980:Levodopa; D001545:Benserazide; D003024:Clozapine